Videos

Preeya Gupta, MD, walks through her four pearls for successful corneal collagen cross-linking, including handling patient expectations, managing the epithelial cells and preventing infectious keratitis.

Firas Rahhal, MD, discusses Outlook Therapeutics’ Phase 3 pivotal NORSE TWO trial for ONS-5010.

Joshua Mali, MD, shares how the FDA-approved faricimab-svoa (Vabysmo, Genentech) will change the treatment landscape for wet AMD and DME.

This program is sponsored by Santen.

This program is sponsored by Santen.

This program is sponsored by Santen.

This program is sponsored by Santen.

This program is sponsored by Santen.

Ted Leng, MD, discusses his IRIS Registry analysis presentation regarding variations in vitreoretinal physician utilization of ancillary testing.

At AAO, AbbVie presented results from the ARTEMIS study, showcasing IOP lowering that extends beyond the original 20-month timeframe.

Jill Hopkins, MD, discusses results from phase 3a of the Merlin trial for brolucizumab as a treatment for wet AMD and provides updates on KESTREL and KITE trials for the treatment of diabetic macular edema.

At the 2021 American Academy of Ophthalmology annual meeting, Penny Asbell, MD, FACS, MBA, discussed data from the ARMOR study and its effects on treating ophthalmic infections, such as endophthalmitis.

Robert H. Osher, MD, shows the merits of drug delivery via capsular bag after cataract surgery.

New cell therapy drug makes treatment of corneal endothelial disease more accessible.

Closing out his discussion on the port delivery system in retinal diseases, Chirag Jhaveri, MD, considers how this approach has impacted the treatment landscape.

Ahmad Aref, MD, and Paul Singh, MD, offer a recap of their EyeCon 2021 presentation.

Hear what Sumayya Ahmad, MD, and Jai G. Parekh, MD, MBA, have to say about current concepts for the management and treatment of dry eye.

Jay Duker, MD, discusses EYP-1901, EyePoint Pharmaceuticals’ sustained-release anti-VEGF drug for the treatment of wet AMD.

Concise insight on education and training strategies that will optimize use of the port delivery system in retinal diseases.

At AAO 2021, Aerie Pharmaceuticals presented the results of their phase 2b clinical trial of AR-15512, a triple 8 antagonist, for the treatment of dry eye.

Mohamed Abou Shousha, MD, PhD, discusses Heru’s wearable AI-powered diagnostic devices at AAO 2021.

Chirag Jhaveri, MD, reviews the trial design and results of the LADDER and ARCHWAY studies, which tested the port delivery system in neovascular AMD.

Verana Health showcases the VeraQ quality measures dashboard for the IRIS registry report at AAO 2021.

Expert insight on the history of the port delivery system in neovascular AMD and how it has impacted patient experience and outcomes.

Sotrovimab, a monoclonal antibody, appears to reduce the risk of progression of mild-to-moderate cases of COVID-19 in patients at high risk of progression.

Sunir J. Garg, MD, speaks on the influence of COVID-19 universal face masking on the risk of endophthalmitis following intravitreal anti-VEGF injections.